Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Valortim, or one or more of its selected
formulation components, induces a wheal reaction when introduced percutaneously.
Two of 4 subjects dosed in a previous study with a modified formulation of Valortim
experienced treatment related adverse events which were suggestive of allergic or
allergic-like reactions. In order to better characterize these reactions and determine if
they represent allergic or allergic-like reactions to Valortim or one or more of its
components, skin testing of Valortim and selected components on naïve and Valortim-exposed
subjects will be performed in this study
Phase:
Phase 1
Details
Lead Sponsor:
PharmAthene, Inc.
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)